BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35443557)

  • 21. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.
    Zhen S; Bian LH; Chang LL; Gao X
    Mol Clin Oncol; 2014 Jul; 2(4):559-566. PubMed ID: 24940495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y; Zhong R; He J; Ding R; Lin H; Deng Y; Zhou L; Li X; Jiang J; Bao Y; Luo X; Duan C
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
    Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
    Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model.
    Wang H; Liu P; Xu H; Dai H
    Am J Transl Res; 2021; 13(12):14141-14148. PubMed ID: 35035759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
    Azzam AZ; Hashad DI; Kamel NA
    Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
    Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
    Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
    Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
    Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers.
    Yanaranop M; Jantarateptewan N; Tiyayon J; Nakrangsee S
    Int J Gynecol Cancer; 2018 Jul; 28(6):1058-1065. PubMed ID: 29975290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
    Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions.
    Macuks R; Baidekalna I; Donina S
    Tumour Biol; 2012 Oct; 33(5):1811-7. PubMed ID: 22696162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer.
    Li H; Sun L; Chen L; Kang Z; Hao G; Bai F
    J Med Biochem; 2022 Feb; 41(1):71-78. PubMed ID: 35431651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.